


Express Mail Label No: EL955088233US
Date of Deposit: June 13, 2002

Attorney Docket No. 18989-006



TECH CENTER 1600/2900

JUN 26 2002

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Chapman *et al.*
SERIAL NUMBER: 09/697,613 EXAMINER: Not Yet Assigned
FILING DATE: October 26, 2000 ART UNIT: 1615
FOR: METHODS OF TREATING VASCULAR DISEASE ASSOCIATED WITH
CYSTATIN C DEFICIENCY

Assistant Commissioner for Patents
Washington, D.C. 20231

RESPONSE TO RESTRICTION REQUIREMENT

In response to the Restriction Requirement mailed December 13, 2001 in the above-identified application, Applicants elect Group I, Claims 1-14 drawn to a method of treating or preventing vascular disease. In response to the species election Applicants elect arteriosclerosis as the vascular disease, cystatin C as the cysteine protease inhibitor and cathepsin S as the cysteine protease. Applicants make this election without prejudice to pursuing non-elected subject matter in later applications.

A response to the Restriction Requirement is due on or before June 13, 2002 with at five-month extension of time. A petition for extension of time is enclosed herewith. Should any additional fee be due, the Commissioner is hereby authorized to charge the fee, or credit any overpayment, to Deposit Account No. 50-0311, Reference No. 18989-006 (BWH-6).

Respectfully submitted,

Ivor R. Elrifi, Reg. No. 39,529
Cynthia A. Kozakiewicz, Reg. No. 42,764
Attorneys for Applicants
c/o MINTZ, LEVIN
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

Dated: June 13, 2002

Express Mail Label No.: EL955088253US
Date of Deposit: June 13, 2002

Attorney Docket No.: 18989-006



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Chapman *et al.*
SERIAL NUMBER: 09/697,613 EXAMINER: Not Yet Assigned
FILING DATE: October 26, 2000 ART UNIT: 1615
FOR: METHODS OF TREATING VASCULAR DISEASE ASSOCIATED WITH
CYSTATIN C DEFICIENCY

RECEIVED
JUN 26 2002
TECH CENTER 1600 12900

Assistant Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Prior to examination of the above-identified application, please amend the application as set forth below.

In the Claims:

Please cancel claims 2-4, and 15-21, without prejudice or disclaimer as being drawn to the non-elected invention.

Please replace the pending claims with the following:

A1 ~~15~~ (amended) A method of treating atherosclerosis in a subject, comprising administering to said subject an inhibitor of a cysteine protease.

A2 5. (amended) The method of claim 1, wherein the cysteine protease is consisting of cathepsin S.

6. The method of claim 1, wherein said inhibitor comprises a cystatin.
7. The method of claim 1, wherein said inhibitor comprises a cystatin C polypeptide.
8. The method of claim 7, wherein said polypeptide comprises a cystatin C active site.
9. The method of claim 1, wherein said inhibitor is administered locally to a site of vascular injury.